- Sobi’s fourth-quarter revenue amounted to SEK 7.44 billion, slightly above the estimate of SEK 7.39 billion.
- The company’s EBIT (Earnings Before Interest and Taxes) was SEK 1.66 billion, close to the estimate of SEK 1.7 billion.
- Analysts’ recommendations include 12 buys, 3 holds, and 1 sell.
A look at Swedish Orphan Biovitrum AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Swedish Orphan Biovitrum AB (SOBI) shows promising potential for long-term growth, supported by favorable scores in Growth, Resilience, and Momentum as per Smartkarma Smart Scores. With a solid Growth score of 3, the company is positioned well for expansion in the future. Additionally, a Resilience score of 3 indicates a robust ability to weather challenges, providing stability in the long run. Momentum, with a score of 4, suggests strong market performance and investor interest in SOBI’s offerings.
While the company scores lower in Dividend, with a score of 1, the overall outlook remains positive for Swedish Orphan Biovitrum AB due to its competitive scores in key areas essential for long-term success. As a bio-pharmaceutical and bio-technology firm specializing in therapies for various diseases, including haemophilia and inflammation, SOBI caters to a global clientele, positioning it well for sustained growth and innovation in the pharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
